Pfizer (PFE) EPS (Basic) (2009 - 2026)

Pfizer has disclosed EPS (Basic) across 17 years of filings, most recently posting -$0.0 for Q1 2026.

• In Q1 2026, EPS (Basic) changed N/A year-over-year to -$0.0; the TTM figure through Mar 2026 stood at $0.0 (up 32.96% YoY), while the FY2025 annual figure was $0.0, up 126.51% from the prior year.
• EPS (Basic) slipped to -$0.0 in Q1 2026, from $0.0 in the prior quarter.
• Over the last five years, EPS (Basic) for PFE reached as high as $0.01 in Q3 2022 and fell as low as -$0.0 in Q4 2023.
• The 5-year median for EPS (Basic) is -$0.0 (2024), against an average of $0.0.
• Annual changes were most pronounced in 2022 — EPS (Basic) slumped 994.71% — and 2024, when it jumped 947.0%.
• A 5-year view of EPS (Basic) shows it stood at -$0.0 in 2022, then fell by 23.02% to -$0.0 in 2023, then soared by 69.36% to -$0.0 in 2024, then jumped by 411.51% to $0.0 in 2025, then sank by 151.95% to -$0.0 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.0, $0.0, and -$0.0 for Q1 2026, Q2 2025, and Q3 2024 respectively.